Mediterranean diet and its role in the prevalence of metabolic syndrome;Rol de la dieta Mediterránea en la prevalencia del sindrome metabólico

Revista Chilena de Nutricion

Volumn 34, Issue 3, 2007, Pages

  Valenzuela B , Andrea ^a   Arteaga Ll , Antonio ^a   Rozowski N , Jaime ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Life style; Mediterranean diet; Metabolic syndrome

Indexed keywords

EID: 36148936397     PISSN: 07177518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. MINSAL, Departamento de Epidemiología, Situación de Salud de Chile, 2002.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001. 285:2486-2497.
3. Reaven G. Role of insulin resistance in human disease. Diabetes 1988. 37:1595-607.
4. WHO consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. WHO/NCD/NCS/99.2; 31-3.
5. Facchini F, Chen Y-DI, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991. 266: 3008-11.
6. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med 2001. 250 (2): 105-20.
7. Erkelens DW. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol 2001. 11; 88 (7B): 38J-42 J.
8. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment panel III). Executive summary. NIH Publication 01-3670; May 2001.
9. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003. 26: 575-581.
10. Liao Y, Kwon S, Shaughnessy S, Wallace P, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004. 27:978-983.
11. Marchesini G, Forlani G, Cerrelli F, Manini R, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 2004. 21:383-387.
12. Wyszynski DF, Waterworth DM, Barter PJ, Grundy SM, et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiolgoy of Metabolic Syndrome Project). Am J Cardiol 2005. 95:194-198.
13. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004. 27:1182-1186.
14. Enkhmaa B, Shiwaku K, Anuurad E, Nogi A et al. Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians. Clin Chim Acta 2005. 352: 105-113.
15. Thomas GN, Ho SY, Janus ED, Lam KS, Hedley AJ, Lam TH; Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 2005. 67:251-257.
16. Shiwaku K, Nogi A, Kitajima K, Anuurad E, et al. Prevalence of the metabolic syndrome using the modified ATP III definitions for workers in Japan, Korea and Mongolia. J Occup Health 2005; 47:126-135.
17. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004. 110:1251-1257.
18. Genuth S, Alberti KG, Bennett P, Buse J, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003. 26: 3160-3167.
19. Ford ES, Giles WH, Dietz WH: Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002. 287:356-359.
20. Ferrannini E. Natali A. Essential hypertension, metabolic disorders and insulin resistence. Am Heart J 1991. 121:1274-1282.
21. Isomaa B, Almgren P, Tuomi T, Forsen B,. Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diabetes Care 2001. 24: 683-689.
22. Kim ES, Han SM, Kim YI, Song KH, Kim MS, Kim WB, Park JY, Lee KU. Prevalence and clinical characteristics of metabolic syndrome in a rural population of South Korea. Diabet Med. 2004; 21:1141-3. Diabetes Care 2001. 24:683-9.
23. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, DECODE Study Group. Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and Women. Arch Intern Med 2004;164:1066-1076.
24. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 2004; 147:106-12.
25. Appel L, Moore T, Obarzanek E, Vollmer W, Svetkey L, Sacks F, Bray G, Vogt T, for the DASH Collaborative Research Group, et al. A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure. N Engl J Med 1997; 336:1117-24.
26. Appel L, Miller E; Jee S, Stolzenberg-Solomon R, et al. Effect of Dietary Patterns on Serum Homocysteine: Results of a Randomized, Controlled Feeding Study. Circulation 2000; 102(8):852-857.
27. Trevor J. Orchard, Marinella Temprosa, Ronald Goldberg, Steven Haffner, Robert Ratner, Santica Marcovina, Sarah Fowler for the Diabetes Prevention Program Research Group. The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome. Ann Intern Med 2005; 142:611-619.
28. Keys A. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, Mass: Harvard University Press. 1980.
29. Masana L, Camprubi M, Sarda P, Sola R, Joven J, Turner PR. The Mediterranean-type diet: is there a need for further modification? Am J Clin Nutr; 1991. 53:886-889.
30. Sacks FM, Willett W. Chewing the fat: how much and what kind? N Engl J Med. 1991; 324:121-123.
31. Willett WC. Diet and health: what should we eat? Science 1994; 264:532-537.
32. Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 1995; 61:1402S-1406S.
33. Trichopoulou A, Kouris-Blazos A, Wahlqvist ML, et al. Diet and overall survival in the elderly. BMJ 1995; 311:1457-1460.
34. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to Mediterranean diet and survival in a Greek population. N Engl J Med 2003;348:2599-2608.
35. Osler M, Schroll M. Diet and mortality in a cohort of elderly people in a north European community. Int J Epidemiol 1997; 26:155-159.
36. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292:1433-1439.
37. Trichopoulou A, Lagiou P, Kuper H, Trichopoulos D. Cancer and Mediterranean dietary traditions. Cancer Epidemiol Biomarkers Prev. 2000; 9:869-873.
38. Panagiotakos DB, Pitsavos C, Chrysohoou C, Tzioumis K, et al. The Association of Mediterranean Diet with Lower Risk of Acute Coronary Syndromes, in Hypertensive Subjects. Int J Cardiol 2002; 19:141-147.
39. Trichopoulou A, Lagiou P. Healty tradiotional Mediterranean diet - An espression of culture, history and lifestyle. Nutr Rev 1997; 55:383-389.
40. Ros E, Fisac C, Pérez-Heras A. ¿Por qué la dieta mediterránea? Fundamentos Científicos. Clin. Invest. Arteriosclerosis 1998; 10:258-268.
41. Varela G. Frying food in olive oil. Madrid: Consejo Oleícola Internacional, 1994.
42. Montedoro G, Servili M, Baldioli M, Miniati E. Simple and hydrolyzable phenolic compounds in virgin olive oil. J. Agric. Food Chem 1992; 9:571-1576.
43. Marrugat J, Covas MI, Fito M, Schroder H, et al. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation - a randomized controlled trial. Eur J Nutr 2004; 43:140-7.
44. Moreno JA, Lopez-Miranda J, Gomez P, Benkhalti F, et al. Effect of phenolic compounds of virgin olive oil on LDL oxidation resistance. Med Clin (Barc) 2003. 8:120; 4:128-31.
45. Gimeno E, Fito M, Lamuela-Raventos RM, Castellote AI, et al. Effect of ingestion of virgin olive oil on human low-density lipoprotein composition. Eur J Clin Nutr 2002. 56:114-20.
46. Carluccio MA, Siculella L, Ancora MA, Massaro M,et al. Olive Oil and Red Wine Antioxidant Polyphenols Inhibit Endothelial Activation: Antiatherogenic Properties of Mediterranean Diet Phytochemicals. Arterioscler Thromb Vasc Biol 2003; 23:622-629.
47. Fuhrman B, Aviram M. Anti-atherogenicity of nutritional antioxidants. IDrugs 2001;4(1):82-92.
48. Harris WS. Extending the Cardiovascular Benefits of Omega-3 Fatty Acids. Curr Atheroscler Rep 2005; 7:375-380.
49. Arija Val V, Babio N, Fernandez-Ballart J, Serra-Majem L. Mediterranean Diet and the sea: fish. Arch Latinoam Nutr; 2004; 54:72-5.
50. Kris-Etherton P, Harris W, Appel L. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation 2002; 106:2747-2757.
51. Burton, G. W. y Traber, M. G. Vitamin E. Antioxidant activity, biokinetics and bioavailability. Amer. Rev. Nutr; 1990; 10:357-382.
52. Hertog M, Feskens E, Hollman P, Katan M, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342:1007-1011.
53. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ. 1996; 312:478-481.
54. Esposito K, Marfella R, Ciotola M, Di Palo C, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292:1440-6.
55. Rosell M, De Faire U, Hellenius ML. Low prevalence of the metabolic syndrome in wine drinkers - is it the alcohol beverage or the lifestyle? Eur J Clin Nutr 2003; 57:227-234.
56. Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R; Third National Health and Nutrition Examination Survey. Alcohol consumption and the prevalence of the Metabolic Syndrome in the US.: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004,27:2954-9.
57. Rotondo S, de Gaetano G. Protection from cardiovascular disease by wine and its derived products. Epidemiological evidence and biological mechanisms. World Rev Nutr Diet 2000; 87:90-113.
58. Psaltopoulou T, Naska A, Orfanos P, Trichopoulos D, Mountokalakis T, Trichopoulou A. Olive oil, the Mediterranean diet, and arterial blood pressure: the Greek European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr 2004; 80:1012-1018.
59. Paschos GK, Rallidis LS, Liakos GK, Panagiotakos D,et al. Background diet influences the anti-inflammatory effect of alpha-linolenic acid in dyslipidaemic subjects. Br J Nutr 2004; 92:649-55.
60. Estruch R, Martínez-González M, Corella D, Salas-Salvado J, y colaboradores. Effects of a Mediterranean Style Diet on Cardiovascular Risk Factors. Ann Intern Med 2006;145:1-11.